Innovation for women’s health
We are one of the few healthcare companies dedicated to advancing scientific innovations that support women’s health.
Our focus areas
We focus our efforts on areas where critical therapeutic gaps exist in women’s health. We take a broad view of women’s health and focus our R&D efforts on pursuing opportunities that address conditions that are unique to women, affect her disproportionately or impact her differently. They include:
- Maternal and peripartum conditions (post-partum hemorrhage, preeclampsia, preterm labor)
- Infertility
- Unintended pregnancy (contraception)
- Conditions unique to women (endometriosis, polycystic ovarian syndrome, menopause)
- Conditions affecting women disproportionally (migraine, urinary incontinence, autoimmune diseases)
- Conditions affecting women differently (mental health, cardiovascular disease, cancer)
We are actively pursuing medical products, including drugs, devices, diagnostics and digital solutions that have the potential to address the complete health of women, particularly where therapeutic gaps exist.
- By taking a broad view of women’s health, we are pursuing innovations to address the health of the whole woman across her life span.
- Many conditions affect women at every stage of life, and there remain many areas of high and unmet needs in therapeutic options for treating these conditions.
Women play a critical role* in maintaining their family’s health, and by prioritizing their own health they can positively impact the health of their family. When we invest in women’s health, we’re investing in individual women, their families, communities as well as their country’s economy and future.
- Women will spend an average of nine years** in poor health (25% more than men).
- On average, women are diagnosed significantly later than men across more than 700 diseases***, including cancer.
Progress on goals
- Aim to redefine and harness innovation in women’s health by dedicating a majority of our pre-clinical and clinical development activity toward areas of unmet health needs in conditions that are unique to women, affect her disproportionately or impact her differently.
- Seek collaborations to expand access to treatment options that improve her health and help secure her promise.
- Strive to engage the women’s health innovation ecosystem – NGOs, start-ups, venture capital and others – to think creatively about how to support the best science and accelerate access to new medicines, devices and solutions for women and girls around the world.
- Seek potential solutions that can achieve a significant impact by improving care, diagnosis, quality of life and health outcomes for women.
Research and development
Since our launch in 2021, Organon has been building an R&D portfolio that includes a variety of innovative assets across women’s health inclusive of clinical stage trials and commercialized medicines and devices.
Our research interests include:
- A biosimilars commercialization agreement/collaboration to treat breast cancer and osteoporosis
- Postpartum hemorrhage, a major contributor to maternal morbidity
- Endometriosis-related pain, a common and chronic condition affecting up to one in 10 women of reproductive age globally.
- Hormone-free, on-demand contraception, an option preferred by many women who have few effective alternatives
- An option to acquire a device for use during minimally invasive laparoscopic hysterectomy
Collaboration and partnerships for innovation
We know that healthy women are the bedrock of a thriving, stable and resilient society.
By convening and catalyzing an ecosystem of like-minded partners and innovators, we can spark collective action to deliver a new era in healthcare — improving research, enhancing education, investing in partnerships to expand options and advancing gender equity. Our goal is to nurture this ecosystem to advance the field and improve women’s lives.
By engaging in partnerships with innovators across the healthcare ecosystem, including companies, academic institutions, foundations, NGOs, venture capital and healthcare providers, we aim to identify emerging science and accelerate access to new medicines, devices and solutions for women and girls around the world.
Learn more about our work in business development
Fostering innovation throughout the R&D pipeline
Organon is dedicated to pursuing scientific innovations for women’s health, prioritizing areas where critical therapeutic gaps exist. Our goal is to build an industry-leading pipeline of therapeutics and devices to address women’s unmet needs — with both early and late-stage assets focused on our four therapeutic cornerstones: contraception, fertility, maternal and peripartum conditions (postpartum hemorrhage, preeclampsia, preterm labor) and conditions unique to women (endometriosis, fibroids, PCOS, menopause). Through a focused and active external innovation strategy, Organon is constantly exploring emerging science with the opportunity to provide better healthcare solutions for women.
Learn more about our work on product quality and safety and access to medicines and healthcare
*The Health of Women and Girls Determines the Health and Well-Being of Our Modern World: A White Paper From the International Council on Women’s Health Issues – PMC, National Library of Medicine
**Closing the women’s health gap: A $1 trillion opportunity to improve lives and economies, McKinsey Health Institute
***Closing the women’s health gap: A $1 trillion opportunity to improve lives and economies, McKinsey Health Institute